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Introduction
Research, started over a century ago, on human milk oligosaccharides 
(HMOs) has focused predominantly on their prebiotic effects. Today 
it is known that the bifidogenic effects of HMOs are one of the many 
beneficial effects now being discovered.1 In addition to providing a 
substrate for the growth of beneficial bacteria, HMOs also directly 
inhibit pathogens from adhering to the intestinal epithelia through 
their antiadhesive properties.1 Recent data suggest that firstly, 
a relationship exists between the HMOs and the incidence of 
necrotising enterocolitis (NEC),2,3 and secondly, they may have an 
influence on human immunodeficiency virus (HIV) transmission.4 
This article aims to describe the prebiotic and antiadhesive effects of 
HMOs, and how they could possibly prevent the development of NEC 
in the presence of HIV infection.
Human milk oligosaccharides
HMOs5,6 are complex carbohydrates that are highly abundant 
in breast milk, but not in infant formula.7 Oligosaccharides are 
carbohydrates made up of 3-9 monosaccharide units.5,6 The 
oligosaccharide concentration of human milk varies with gestational 
age, lactation duration, and from one mother to another.6,8 HMOs 
reach the highest concentration in colostrum (20-25 g/l), and then 
decrease after roughly two weeks to approximately 5-20 g/l in 
mature breast milk.1,6,8-11
HMOs consists of five different monosaccharide units: 
•	 Glucose.
•	 Galactose.
•	 The sialic acid component, known as N-acetylglucosamine.
•	 Fucose.
•	 N-acteylneuaminic acid.1,12 
With a few exceptions, all HMOs contain lactose at their reducing end. 
They may be elongated (an enzymatic attachment) by the addition 
of β1-3- or β1-6-linked lacto-N-biose or N-acetyllacetosamine. 
The latter can be further extended by one or two disaccharides. 
Chain branching may occur at the β1-6 linkage. Branched lactose 
molecules may form both linear (para-HMOs) and branched 
structures (iso-HMOs). Furthermore, oligosaccharide chains can 
be fucosylated (also known as neutral oligosaccharides) in the 
α1-2, α1-3 or α1-4 linkage, or sialylated (also known as acidic 
oligosaccharides) in the α2-3 or α2-6 linkage. The ABH secretor (Se) 
status and Lewis (Le) blood group determines the HMO composition 
of a mother’s breast milk.1 The presence or absence of blood group 
substances (A, B and H) in the saliva and other body secretions is 
controlled by a gene on chromosome 19, the fucosyltransferase 
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locus 2 and the fucosyltransferase locus 3.13 Both genes are 
expressed in glandular epithelia and have dominant allele (Le and 
Se, respectively) coding for enzymes with fucosyltransferase activity 
and recessive alleles (le and se, respectively) that are not functional. 
Briefly, the fucosyltransferase encoded by the Se gene regulates the 
synthesis of HMOs containing fucose with an α-1,2 linkage. The Le 
gene promotes the synthesis of α-1,3 and α-1,4 linkages.1 There 
are up to 200 identified HMOs and their effects appear to be strongly 
structure dependent.8,11 
An atypical characteristic of HMOs is that the monosaccharides, of 
which they are comprised, are bound by specific bonds resistant 
to the digestive enzymes present in the small intestine.8,14 Although 
intact HMOs may be absorbed, the majority of oligosaccharides 
ingested through breast milk pass through the small intestine 
undigested, and reach the colon where they act as a fuel source 
for bifidus-predominant bacteria, thereby gaining the status of 
prebiotics.1,15,16 A small percentage of absorbed HMOs are excreted 
in the urine,8,11 and may protect the infant from urinary tract 
infections.17 High proportions of bifidobacteria are represented in the 
intestinal tract of breastfed infants, and through the generation of 
short-chain fatty acids, they protect the enterocyte from pathogens, 
and may contribute to mucosal integrity.8,11,17 
HMO functionality is not limited to their prebiotic effects only. The 
possibility was raised more than a decade ago that HMOs may act 
as an anti-infective agent by blocking pathogen adhesion to the 
intestinal epithelial cell walls, thereby possibly preventing enteric 
infections, such as rotavirus diarrhoea and systemic infections, such 
as HIV/acquired immune deficiency syndrome.17 The anti-infective 
effect that they hold has generated considerable interest. The 
bifidogenic and anti-adhesive properties of HMOs, as well as their 
role in NEC and the possible linkage to HIV, are now be described in 
further detail. 
The bifidogenic (prebiotic) effect of human milk 
oligosaccharides 
Factors that influence gastrointestinal tract colonisation can 
be grouped into two categories: extrinsic and intrinsic. Intrinsic 
factors include underlying neonatal health, immunological status, 
gastrointestinal transit time and pH. These factors affect the process 
of colonisation and the types of organisms established in the 
neonatal intestinal tract. Extrinsic factors include the geographical 
area, maternal and surrounding environment bacteria, mode of 
delivery, feeding practices and drug therapies.18 
It is well established that the type of delivery has a significant 
influence on the development of intestinal microflora.19,20 Infants 
born by vaginal delivery are more exposed to their mother’s 
microbiota than those born by Caesarean section.19 Initial exposure 
to microflora by those born by Caesarean delivery is most likely to 
be from environmental micro-organisms on the equipment, in the 
air and on other neonates, with the nursing personnel acting as 
carriers.20
Furthermore, the preterm infant is exposed to bacteria in the neonatal 
intensive care unit, where the frequent use of broad-spectrum 
antibiotics affects the colonisation of health-promoting bacteria.21 
The choice of feed plays an important role in the establishment 
of intestinal flora. Bifidobacterium is a predominant organism 
found in the intestinal tract of breastfed infants. Lactobacillus and 
Streptococcus are found in lesser quantities. By contrast, similar 
amounts of bacteroides and bifidobacterium are found in formula-fed 
infants, as well as components of the more pathogenic species, such 
as Staphylococcus, Escherichia coli and Clostridia.21 An extraordinary 
characteristic of the intestinal environment of breastfed infants is 
the selective nourishment and protective support provided by the 
intestinal microbiotia.22 
The term “prebiotic” was introduced and defined by Gibson and 
Roberfroid as “a non-digestible food ingredient that beneficially 
affects the host by selectively stimulating the growth and/or activity 
of one or a limited number of bacteria in the colon”.23,24 Although 
HMOs fully conform to this definition, it is important to bear in 
mind that HMOs promote the growth of certain, but not all, health-
promoting bacteria.1 Glycoprofiling results by LoCascio et al22 
provide molecular and mechanistic evidence that specific strains of 
bifidobacteria have an affinity for selected classes of HMO.8,11 This 
suggests that the diversity of specific oligosaccharide structures 
found within human milk do not provide a direct source of nutrition to 
the infant, but rather act as specific substrates to assist the growth 
of selected beneficial bacteria, that in their own right support the 
development and protection of the neonate.22 N-acetylglucosamine 
oligosaccharides have been implicated as important cell wall 
components for bifidobacteria.17 In the case of B. longum by 
infantis, this strain has the ability to preferentially consume the most 
abundant HMOs.11,22 
Antiadhesive effect of human milk oligosaccharides
There is increasing evidence that oligosaccharides in human milk 
have a direct inhibitory effect on certain virulence capabilities 
of pathogenic microorganisms.11 The destructiveness of most 
pathogenic microorganisms, e.g. Campylobacter jejuni, E. coli 
and Salmonella strains, often depends on their aptitude to adhere 
to epithelial surfaces.25 In general, bacterial adhesion is a ligand-
receptor interaction between structures on the bacterial surface and 
complementary structures on the mucosal surface of the host.11 
HMOs structurally imitate epithelial cell surface carbohydrates, and 
therefore act as decoys to which infectious agents can bind, instead 
of to the host, thereby preventing possible infection.26,27 These 
molecules can withstand the low pH of the stomach, and resist 
degradation through enzymes from the pancreas and brush border 
membrane.28 With every feed, the gut of breastfed infants is flushed 
with various oligosaccharides that can effectively reach and block 
binding sites, thereby reducing the chances of probable pathogen 
adhesion to these locations.26 
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Human immunodeficiency virus and human milk 
oligosaccharides 
Breastfeeding is the predominant postnatal transmission route for 
HIV-1 infection in children.29 However, the majority of breastfed 
infants do not become HIV-infected, despite continuous exposure to 
the virus through their mothers’ milk over many months. This raises 
the question: Does human milk have properties that protect the 
infant against HIV transmission? 
Dendritic cell-specific intercellular adhesion molecule-3-grabbing 
nonintegrin (DC-SIGN)-bound pathogens are usually transferred 
into dendritic cell (DC) lysosomes, where they are processed before 
stimulating T cells to initiate an immune response.25 However, HIV-1 
pathogens are kept hidden within the DC for a number of days without 
prompting an immune response before they are transferred to CD4+ 
T lymphocytes, where they multiply and cause disease at a later 
stage.11,30 DC-SIGN is a carbohydrate-binding protein. It recognises 
mannose-containing glycoconjugates, such as HIV-1-gp120, with 
an even higher binding affinity for Le blood group antigens.25,29,31 
Although monomeric Le epitopes bind to DC-SIGN, the presence of 
multivalent Le epitopes is required to compete with HIV-1-gp120 
for DC-SIGN-binding. The occurrence of multiple Le blood group 
determinants as part of HMOs led scientists to postulate that HMOs 
compete with HIV-1-gp120 for binding to DC-SIGN, and therefore 
play a protective role against HIV-1 mother-to-child transmission 
during breastfeeding.1,25 Since some HMOs structurally resemble 
the Le blood group antigens that show high-binding affinity for DC-
SIGN, and some HMOs carry one or multiple Le epitopes, HMOs 
may compete with gp120 for binding to DC-SIGN and reduce HIV-1 
mother-to-child transmission.31,32 
However, the results by Bode et al suggest otherwise.4 They found 
that the concentration of HMOs with secretor or Le-active epitopes 
did not correlate with HIV transmission risk. These results propose 
that the protection against postnatal HIV transmission is probably 
independent of the mother’s secretor or Le blood group status, and 
that HMOs offer other protective properties, i.e. concentrations of 
lacto-N-neotetraose.4 As described, more than 200 different HMOs 
have been characterised, and investigators have speculated whether 
or not the amount will rise to 1 000. Hong et al described the blocking 
of the DC-SIGN as a two-edged sword, indicating that although it 
may reduce the entrance of certain viruses, such as HIV-1, at the 
same time it may also reduce the ability of the infant’s immune 
system to detect and fight other pathogens, leading to a potentially 
increased risk of bacterial or viral gastroenteritis.29 Hong et al have 
shown that physiological concentrations of HMOs significantly 
reduce HIV-1gp120-binding to DC-SIGN.25,29 Therefore, the question 
is: Which HMOs are the most potent inhibitors of HIV-1-gp120–DC-
SIGN binding?29 Once individual HMOs have been identified that 
block HIV-1-gp120 binding to DC-SIGN, it will be important to assess 
whether or not these HMOs trigger adverse effects.25 
Necrotising enterocolitis 
NEC is the most common serious acquired condition of the 
gastrointestinal tract in preterm infants.33 NEC occurs in 4-11% 
of all premature infants born with a very low birthweight, and an 
inverse relationship exists between birthweight, gestational age and 
the incidence of NEC.33,34 Generally, prematurity, enteral feeding, 
ischaemia and bacterial colonisation are the most common risk 
factors for the development of NEC.35-38 The pathogenesis of NEC 
in neonates born to HIV-infected mothers has not been clearly 
elucidated. Some described contributing factors include maternal 
antiretroviral treatment, maternal sepsis and immunological 
abnormalities. Although antiretroviral prophylaxis has decreased the 
perinatal transmission of HIV, the burden of NEC in the HIV-exposed 
newborn population is significant.39,40 Infants who receive human 
milk show a reduced incidence of NEC, compared to those receiving 
infant formula.41 Numerous advantages of breast milk have been 
found over infant formula. These include the earlier achievement of 
full enteral feeding, the presence of active enzymes which enhance 
the maturation of the immature intestinal tract, and anti-infective 
agents which protect the neonate from infections.42 The effect of 
prebiotics on NEC has not been studied partly because of the very 
large sample sizes that are required, and secondly because of ethical 
concerns with such trials. 
Jantscher-Krenn et al found that disialyllacto-N-tetraose (DSLNT) 
has a protective effect against the development of NEC in neonatal 
rats.2 Results by Van Niekerk et al3 indicate that DSLNT may indeed 
protect against NEC, not only in neonatal rats as indicated by 
Jantscher-Krenn et al, but also in human preterm infants. These 
results suggest that infants diagnosed with NEC received breast 
milk that contained lower concentrations of DSLNT than infants who 
did not develop NEC. Specifically designed and well powered cohort 
studies are required to verify the link between DSLNT and NEC. If 
confirmed, DSLNT concentrations in mothers’ milk could serve as a 
noninvasive marker to determine whether or not a breastfed infant is 
at risk of developing NEC.3 
The role of probiotics in the management of 
necrotising enterocolitis
When focusing on bacterial colonisation, which plays a pivotal 
role in the development of NEC,43,44 it is important to note that no 
single bacterial species has thus far been associated with NEC. 
Although Enterobacteriaceae spp. is the most frequently pronounced 
bacteria to be found in association with NEC, Clostridia spp. and 
Staphylococcus spp. have also been isolated.45 Probiotics might be 
beneficial in preventing the overgrowth of pathogenic organisms, 
increased feeding tolerance,46,47 decreasing the number of days 
until full feeds48 are reached and preventing nosocomial infections. 
Furthermore, probiotics potentially compete with other organisms for 
binding sites and substrate in the bowel.49,50 Microbiota disturbances 
early in HIV infection lead to greater dominance of potential 
pathogens, reduced levels of Bifidobacteria and Lactobacillus spp. 
and increasing mucosal inflammation.51 As HMOs support the 
growth of these beneficial bacteria, it is therefore proposed that 
in conjunction with the use of probiotics, HMOs could potentially 
reduce the risk of NEC. A randomised clinical trial by van Niekerk et 
al was the first to examine the use of probiotics in the management 
of NEC in HIV-exposed versus non-exposed, very low-birthweight 
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infants.52 The results from this trial concluded that the incidence of 
death and NEC did not differ significantly between the HIV-exposed 
and unexposed groups. However, a reduced severity of disease per 
Bell’s staging criteria was found. A significantly lower incidence of 
NEC was found in the probiotic group than in the control group.52 
Because the pathogenesis of NEC involves various complex 
pathways, different probiotic strains may create benefit through 
different pathways. Evidence suggests that the use of a multistrain or 
multispecies probiotic should be more effective and more consistent 
than that of a monostrain probiotic.53 Randomised controlled trials 
that used a multistrain probiotic reported a significant decline in NEC, 
whereas those reporting a lesser decline used a single organism, 
such as L. rhamnosus GG.49,53,54 
Conclusion
HMOs not only act as a substrate for beneficial bacteria, but also 
provide antiadhesive effects, thereby reducing the risk of infection.1 
Many unanswered questions remain that surround the mother-to-
child transmission of HIV and the role of HMOs. Furthermore, the 
incidence of NEC in premature infants has increased as the burden 
of HIV has heightened.55 Therefore, the question remains: Could 
HMOs serve as a prophylactic measure against this life-threatening 
gastrointestinal condition? Further studies are needed to investigate 
the influence of HMOs on the attachment of pathogens to the 
intestinal epithelial cell walls. To fully understand the immunological 
needs of the preterm infant, HMO concentrations in preterm breast 
milk need to be clearly defined. Future prospects for HMO research 
are expected to be very useful with regard to the development of 
management options that are effective in protecting babies from 
harmful infections.
Breast milk is widely recognised as the optimal feed of choice 
for both term and preterm infants, as it upholds metabolic, 
immunological and neurodevelopmental advantages.56 The World 
Health Organization57 recommends exclusive breastfeeding for all 
infants, and recommends modifications to breastfeeding, such as 
breast milk expression and pasteurisation, to reduce the risk of 
HIV transmission, while providing the advantages of breast milk’s 
immune-stimulating properties.58 The use of breast milk should 
be strongly advocated in neonatal units. Postnatal breastfeeding 
practices in resource-limited settings and developing countries 
such as South Africa, can be supported by practising kangaroo 
mother care in neonatal units. A 2012 Cochrane review concluded 
that kangaroo mother care improves anthropometric parameters, 
breastfeeding and mother satisfaction.59 Mothers of preterm infants 
should be encouraged to express their breast milk and pasteurise 
it, if applicable. Breastfeeding must also be enforced when it is 
physiologically possible for preterm infants. 
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In South Africa:
2 in 5 females and 1 in 10 males are obese(1)
DIetAry energy reStrIctIon or phySIcAl ActIvIty In the mAnAgement of obeSIty? IS there An AnSwer?
Yes, restriction of energy intake plUS exercise is more effective for weight loss than exercising or dieting independently. (2)
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plAy An ActIve role
Access the science and expert opinions to debate the role of energy balance in the management of obesity. 
Visit http://beverageinstitute.org/southernafrica/landing_page/energy-balance/...today for more information on energy balance, physical 
activity and nutrition.
The Coca-Cola Company Beverage Institute for Health & Wellness – Southern Africa,  is a resource portal for scientific articles, expert opinions, tools 
and printable downloads to help manage the daily health, wellness and active living of your patients. We would also like to invite you to participate in 
our ongoing CPD Point Programmes, accredited by the Health Professions Council of South Africa.
24785 CCSA Half Page Ad (Journal Clinical Nutrition)25.7.14.indd   1 2014/07/25   9:34 AM
Industry
